S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:CGEN

Compugen Competitors

$8.16
-0.75 (-8.42 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.80
Now: $8.16
$9.10
50-Day Range
$8.91
MA: $12.26
$13.77
52-Week Range
$5.94
Now: $8.16
$19.90
Volume2.32 million shs
Average Volume1.35 million shs
Market Capitalization$558.31 million
P/E RatioN/A
Dividend YieldN/A
Beta2.52

Competitors

Compugen (NASDAQ:CGEN) Vs. KYMR, BCRX, BLUE, VCEL, SRRK, and OCGN

Should you be buying CGEN stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Compugen, including Kymera Therapeutics (KYMR), BioCryst Pharmaceuticals (BCRX), bluebird bio (BLUE), Vericel (VCEL), Scholar Rock (SRRK), and Ocugen (OCGN).

Kymera Therapeutics (NASDAQ:KYMR) and Compugen (NASDAQ:CGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Kymera Therapeutics and Compugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kymera TherapeuticsN/AN/AN/A
CompugenN/A-26.98%-23.28%

Valuation and Earnings

This table compares Kymera Therapeutics and Compugen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera TherapeuticsN/AN/AN/AN/AN/A
Compugen$17.80 million31.37$-27,340,000.00($0.43)-18.98

Kymera Therapeutics has higher earnings, but lower revenue than Compugen.

Analyst Ratings

This is a breakdown of current ratings and price targets for Kymera Therapeutics and Compugen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kymera Therapeutics02402.67
Compugen00703.00

Kymera Therapeutics presently has a consensus target price of $50.3333, indicating a potential upside of 9.75%. Compugen has a consensus target price of $20.7143, indicating a potential upside of 153.85%. Given Compugen's stronger consensus rating and higher probable upside, analysts clearly believe Compugen is more favorable than Kymera Therapeutics.

Insider & Institutional Ownership

37.8% of Kymera Therapeutics shares are held by institutional investors. Comparatively, 63.4% of Compugen shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Compugen beats Kymera Therapeutics on 6 of the 8 factors compared between the two stocks.

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 63.4% of Compugen shares are held by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares BioCryst Pharmaceuticals and Compugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%
CompugenN/A-26.98%-23.28%

Valuation and Earnings

This table compares BioCryst Pharmaceuticals and Compugen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62
Compugen$17.80 million31.37$-27,340,000.00($0.43)-18.98

Compugen has lower revenue, but higher earnings than BioCryst Pharmaceuticals. Compugen is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BioCryst Pharmaceuticals has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for BioCryst Pharmaceuticals and Compugen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCryst Pharmaceuticals03802.73
Compugen00703.00

BioCryst Pharmaceuticals presently has a consensus target price of $11.3750, indicating a potential upside of 4.17%. Compugen has a consensus target price of $20.7143, indicating a potential upside of 153.85%. Given Compugen's stronger consensus rating and higher probable upside, analysts clearly believe Compugen is more favorable than BioCryst Pharmaceuticals.

Summary

Compugen beats BioCryst Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

bluebird bio (NASDAQ:BLUE) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares bluebird bio and Compugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
bluebird bio-256.84%-45.78%-35.14%
CompugenN/A-26.98%-23.28%

Insider and Institutional Ownership

94.3% of bluebird bio shares are held by institutional investors. Comparatively, 63.4% of Compugen shares are held by institutional investors. 3.6% of bluebird bio shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for bluebird bio and Compugen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
bluebird bio013402.24
Compugen00703.00

bluebird bio presently has a consensus price target of $68.4667, indicating a potential upside of 145.05%. Compugen has a consensus price target of $20.7143, indicating a potential upside of 153.85%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than bluebird bio.

Earnings & Valuation

This table compares bluebird bio and Compugen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bluebird bio$44.67 million42.00$-789,610,000.00($14.31)-1.95
Compugen$17.80 million31.37$-27,340,000.00($0.43)-18.98

Compugen has lower revenue, but higher earnings than bluebird bio. Compugen is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

bluebird bio has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.

Summary

Compugen beats bluebird bio on 10 of the 14 factors compared between the two stocks.

Compugen (NASDAQ:CGEN) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Compugen and Vericel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CompugenN/A-26.98%-23.28%
Vericel0.12%0.13%0.10%

Institutional and Insider Ownership

63.4% of Compugen shares are held by institutional investors. Comparatively, 93.1% of Vericel shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 4.3% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Compugen and Vericel, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Compugen00703.00
Vericel02602.75

Compugen currently has a consensus price target of $20.7143, indicating a potential upside of 153.85%. Vericel has a consensus price target of $49.00, indicating a potential upside of 21.26%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than Vericel.

Valuation and Earnings

This table compares Compugen and Vericel's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$17.80 million31.37$-27,340,000.00($0.43)-18.98
Vericel$117.85 million15.76$-9,660,000.00$0.18224.50

Vericel has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Compugen has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500.

Summary

Vericel beats Compugen on 8 of the 14 factors compared between the two stocks.

Compugen (NASDAQ:CGEN) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Compugen and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CompugenN/A-26.98%-23.28%
Scholar Rock-365.84%-80.16%-41.33%

Institutional and Insider Ownership

63.4% of Compugen shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 24.6% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Compugen and Scholar Rock, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Compugen00703.00
Scholar Rock00503.00

Compugen currently has a consensus price target of $20.7143, indicating a potential upside of 153.85%. Scholar Rock has a consensus price target of $61.60, indicating a potential upside of 21.74%. Given Compugen's higher probable upside, analysts plainly believe Compugen is more favorable than Scholar Rock.

Valuation and Earnings

This table compares Compugen and Scholar Rock's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$17.80 million31.37$-27,340,000.00($0.43)-18.98
Scholar Rock$20.49 million83.07$-51,000,000.00($1.85)-27.35

Compugen has higher earnings, but lower revenue than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Compugen has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.

Summary

Compugen beats Scholar Rock on 9 of the 13 factors compared between the two stocks.

Compugen (NASDAQ:CGEN) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Compugen and Ocugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CompugenN/A-26.98%-23.28%
OcugenN/A-47.72%-30.78%

Institutional and Insider Ownership

63.4% of Compugen shares are held by institutional investors. Comparatively, 8.5% of Ocugen shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 3.5% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Compugen and Ocugen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Compugen00703.00
Ocugen01302.75

Compugen currently has a consensus price target of $20.7143, indicating a potential upside of 153.85%. Ocugen has a consensus price target of $4.80, indicating a potential downside of 46.49%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than Ocugen.

Valuation and Earnings

This table compares Compugen and Ocugen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compugen$17.80 million31.37$-27,340,000.00($0.43)-18.98
OcugenN/AN/A$-20,240,000.00($1.48)-6.06

Ocugen has lower revenue, but higher earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Compugen has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, indicating that its stock price is 256% more volatile than the S&P 500.

Summary

Compugen beats Ocugen on 9 of the 12 factors compared between the two stocks.


Compugen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.